To report a case of lichen planus pigmentosus inversus associated with tirzepatide use, highlighting its rarity in patients with Fitzpatrick skin type II.
Key Findings:
Lichen planus pigmentosus inversus developed 6 to 7 months after tirzepatide initiation, a rare occurrence in Fitzpatrick skin type II.
The condition is typically reported in patients with Fitzpatrick skin types III-IV.
No new medications were reported by the patient in the preceding 2 years.
Interpretation:
The timing of the skin reaction supports a potential drug-induced lichenoid eruption, suggesting a need for further investigation into the mechanism.
Limitations:
Causal interpretation is limited due to lack of drug discontinuation or rechallenge.
The report cannot establish incidence or recurrence risk.
No follow-up data on the patient's condition post-treatment.
Conclusion:
This case adds to the limited reports of skin reactions associated with GLP-1 receptor agonists, suggesting a need for further investigation into the mechanisms and broader implications.
